Genomic evolution and epidemiological impact of SARS-CoV-2 omicron subvariants in Taiwan, 2023–2025
Open Access
- 29 November 2025
- journal article
- Published by Elsevier in Journal of Infection and Public Health
- Vol. 19 (2) , 103075
Abstract
No abstract availableKeywords
Funding Information
- Kaohsiung Medical University Hospital (SA11204)
This publication has 20 references indexed in Scilit:
- Antibody evasiveness of SARS-CoV-2 subvariants KP.3.1.1 and XECCell Reports, 2025
- Virological characteristics of the SARS-CoV-2 XEC variantThe Lancet Infectious Diseases, 2024
- The epidemiology and phylogenetic trends of Omicron subvariants from BA.5 to XBB.1 in TaiwanJournal of Infection and Public Health, 2024
- Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variantsThe Lancet Infectious Diseases, 2024
- Virological characteristics of the SARS-CoV-2 KP.2 variantThe Lancet Infectious Diseases, 2024
- The emergence and successful elimination of SARS-CoV-2 dominant strains with increasing epidemic potential in Taiwan’s 2021 outbreakHeliyon, 2023
- Epidemiological characteristics of the three waves of COVID-19 epidemic in Taiwan during April 2022 to March 2023Journal of the Formosan Medical Association, 2023
- The identification and phylogenetic analysis of SARS‐CoV‐2 delta variants in TaiwanThe Kaohsiung Journal of Medical Sciences, 2023
- Risk factors associated with mortality in hospitalized patients with laboratory confirmed SARS-CoV-2 infection during the period of omicron (B.1.1.529) variant predominanceAmerican Journal of Infection Control, 2022
- Data, disease and diplomacy: GISAID's innovative contribution to global healthGlobal Challenges, 2017